|
|
|
|
|||||
|
|
|
Guardant's oncology and screening businesses are expanding at a rapid pace.
New partnerships should drive further gains.
Shares of Guardant Health (NASDAQ: GH) rocketed 28% higher on Thursday after the precision oncology company reported outstanding growth metrics across its key product lines.
Image source: Getty Images.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Guardant's third-quarter revenue soared by 39% year over year to $265.2 million. The gains were broad based. Revenue in the healthcare company's biopharma division jumped 18% to $54.7 million. Sales in its oncology segment leaped 31% to $184.4 million, driven by a roughly 40% increase in oncology tests to 74,000. And revenue in Guardant's promising screening business grew 24-fold to $24.1 million, as Shield screening tests rose to 24,000.
Guardant's adjusted net loss, in turn, narrowed to $48.3 million from $55 million in 2024's Q3.
The Guardant360 liquid biopsy test utilizes advanced genomic technology to help doctors identify suitable treatment options for patients with cancer. It can be used to gather actionable information for people with solid tumors in the lungs, breast, colon, and prostate.
Additionally, Guardant's Shield blood test offers people a relatively easy way to screen for early signs of colon cancer compared to colonoscopies and stool-based testing.
These potentially life-saving benefits have enabled Guardant to form partnerships with major clinical laboratories, such as Quest Diagnostics, and patient advocacy organizations, including the American Cancer Society. These collaborations are helping to fuel Guardant's growth.
"We made incredible progress in screening in the third quarter," Co-CEO Helmy Eltoukhy said. "It has been very rewarding to see Shield take off and hear story after story of patients positively impacted by this pioneering test."
These strong results prompted Guardant to boost its full-year sales outlook. Management now sees revenue rising by 31% to $965 million to $970 million in 2025.
Before you buy stock in Guardant Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Guardant Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $593,442!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,269,127!*
Now, it’s worth noting Stock Advisor’s total average return is 1,071% — a market-crushing outperformance compared to 196% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health and Quest Diagnostics. The Motley Fool has a disclosure policy.
| Oct-30 | |
| Oct-30 | |
| Oct-30 |
Why IBD 50's Guardant Health, Up 137% in 2025, Just Rocketed Again
GH +27.87%
Investor's Business Daily
|
| Oct-30 | |
| Oct-30 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-27 | |
| Oct-27 | |
| Oct-27 | |
| Oct-26 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite